These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15177440)

  • 1. Binding modes of 6,7 di-substituted 4-anilinoquinoline-3-carbonitriles to EGFR.
    Akula N; Bhalla J; Sridhar J; Pattabiraman N
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3397-400. PubMed ID: 15177440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
    Kamath S; Buolamwini JK
    J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles.
    Wissner A; Hamann PR; Nilakantan R; Greenberger LM; Ye F; Rapuano TA; Loganzo F
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1411-6. PubMed ID: 15006373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors.
    Pannala M; Kher S; Wilson N; Gaudette J; Sircar I; Zhang SH; Bakhirev A; Yang G; Yuen P; Gorcsan F; Sakurai N; Barbosa M; Cheng JF
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5978-82. PubMed ID: 17827009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
    Tsou HR; Overbeek-Klumpers EG; Hallett WA; Reich MF; Floyd MB; Johnson BD; Michalak RS; Nilakantan R; Discafani C; Golas J; Rabindran SK; Shen R; Shi X; Wang YF; Upeslacis J; Wissner A
    J Med Chem; 2005 Feb; 48(4):1107-31. PubMed ID: 15715478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).
    Wissner A; Overbeek E; Reich MF; Floyd MB; Johnson BD; Mamuya N; Rosfjord EC; Discafani C; Davis R; Shi X; Rabindran SK; Gruber BC; Ye F; Hallett WA; Nilakantan R; Shen R; Wang YF; Greenberger LM; Tsou HR
    J Med Chem; 2003 Jan; 46(1):49-63. PubMed ID: 12502359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
    Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F
    J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of substituted 2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamine related compounds as fructose-1,6-bisphosphatase inhibitors.
    Rosini M; Mancini F; Tarozzi A; Colizzi F; Andrisano V; Bolognesi ML; Hrelia P; Melchiorre C
    Bioorg Med Chem; 2006 Dec; 14(23):7846-53. PubMed ID: 16908175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of HKI-272 and related compounds for the treatment of cancer.
    Wissner A; Mansour TS
    Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.
    Wissner A; Berger DM; Boschelli DH; Floyd MB; Greenberger LM; Gruber BC; Johnson BD; Mamuya N; Nilakantan R; Reich MF; Shen R; Tsou HR; Upeslacis E; Wang YF; Wu B; Ye F; Zhang N
    J Med Chem; 2000 Aug; 43(17):3244-56. PubMed ID: 10966743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.
    Liechti C; Séquin U; Bold G; Furet P; Meyer T; Traxler P
    Eur J Med Chem; 2004 Jan; 39(1):11-26. PubMed ID: 14987830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, docking studies and anti-inflammatory activity of some 2-amino-5,6,7,8-tetrahydroquinoline-3-carbonitriles and related compounds.
    Abd El-Salam OI; Abou El Ella DA; Ismail NS; Abdullah M
    Pharmazie; 2009 Mar; 64(3):147-55. PubMed ID: 19348335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening of 4-anilinoquinazoline analogues as EGFR kinase inhibitors: importance of hydrogen bonds in the evaluation of poses and scoring functions.
    Aparna V; Rambabu G; Panigrahi SK; Sarma JA; Desiraju GR
    J Chem Inf Model; 2005; 45(3):725-38. PubMed ID: 15921462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
    Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.
    Shaul M; Abourbeh G; Jacobson O; Rozen Y; Laky D; Levitzki A; Mishani E
    Bioorg Med Chem; 2004 Jul; 12(13):3421-9. PubMed ID: 15186828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (EGFR) signaling in cancer.
    Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
    Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
    Forsberg S; Ostman A; Rollman O
    Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-Anilino-3-cyanobenzo[g]quinolines as kinase inhibitors.
    Zhang N; Wu B; Wissner A; Powell DW; Rabindran SK; Kohler C; Boschelli F
    Bioorg Med Chem Lett; 2002 Feb; 12(3):423-5. PubMed ID: 11814812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.
    Cavasotto CN; Ortiz MA; Abagyan RA; Piedrafita FJ
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1969-74. PubMed ID: 16413185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the structural basis of N2 and O6 substituted guanine derivatives as cyclin-dependent kinase 2 (CDK2) inhibitors: prediction of the binding modes and potency of the inhibitors by docking and ONIOM calculations.
    Alzate-Morales JH; Caballero J; Vergara Jague A; González Nilo FD
    J Chem Inf Model; 2009 Apr; 49(4):886-99. PubMed ID: 19323453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.